FFA
FULC icon

Farther Finance Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Farther Finance Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.16K Buy
2,462
+72
+3% +$438 ﹤0.01% 4479
2026
Q1 		$17.9K Buy
2,390
+200
+9% +$1.85K ﹤0.01% 3737
2025
Q4 		$24.8K Sell
2,190
-4,922
-69% -$50.1K ﹤0.01% 3293
2025
Q3 		$65.4K Buy
7,112
+3,697
+108% +$26.7K ﹤0.01% 2293
2025
Q2 		$23.5K Buy
3,415
+1,394
+69% +$7.46K ﹤0.01% 2576
2025
Q1 		$5.58K Buy
+2,021
New +$7.42K ﹤0.01% 3005

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Farther Finance Advisors's FULC Position: Q2 2026 in Review

Farther Finance Advisors increased its Fulcrum Therapeutics (FULC) stake by 3% in Q2 2026, buying an estimated $438 and bringing the position to 2,462 shares worth $9.16K. The position accounts for ﹤0.01% of the portfolio, ranked #4479.

Farther Finance Advisors first reported a position in FULC in Q1 2025 and has held it in 6 quarters since. The position peaked at $65.4K in Q3 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Farther Finance Advisors held 2,462 shares of Fulcrum Therapeutics worth $9.16K as of Q2 2026.
  • Farther Finance Advisors bought 72 Fulcrum Therapeutics shares in Q2 2026, an estimated $438.
  • Fulcrum Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4479 holding.
  • Farther Finance Advisors first reported a position in Fulcrum Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Farther Finance Advisors's Fulcrum Therapeutics position peaked at $65.4K in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.